Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (July 2021)
38 slides from Nemaura Medical's investor presentation, Jul 26, 2021
Slide 1: Corporate Presentation July 2021
Corporate Presentation July 2021 Nasdaq : NMRD
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties . These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms suc
Slide 3: Introduction
Introduction We developed the world’s first Daily - Wear non - invasive Continuous Glucose Monitor (CGM) – A Class 2b CE approved Medical Device. Launched: sugarBEAT ® and BEAT ® diabetes , supporting Diabetes prevention, management and reversal. Planned Launch in 2021: Mass Market consumer metaboli
Slide 4: The Problem
The Problem… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the US alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major drivers of
Slide 5: Our Objective: Prevent, Manage, or Reverse Type 2 Diabetes
Our Objective: Prevent, Manage, or Reverse Type 2 Diabetes
Slide 6: Our Unique Solution
UNIQUE The world’s first daily wear CGM: no other sensor technology is currently available allowing non - invasive daily use. LIFESTYLE Other competing sensors are worn for 10 - 14 days consecutively. Nemaura’s BEAT® sensors are designed for daily use – any day you choose. Our Unique Solution KNOWLE
Slide 7: Our Approach
Our Approach 1. sugarBEAT ® CGM – real time glucose monitoring. 1. BEAT ® diabetes – Digital program for diabetes management and reversal, with intermittent glucose profiling. 1. Mass market consumer metabolic health App and Glucose Sensor Kit, targeting obesity, pre - diabetes and Type 2 diabetes.
Slide 8: Total Addressable Market
Total Addressable Market UK 4.8 million people with diabetes 8 One person diagnosed every 2 minutes Germany 9.5 million have diabetes 9 . 4.5 million of these 9.5 million are undiagnosed and, as a result, may be particularly at risk. U.S. 34.2 million have diabetes 6 88 million people have pre - dia
Slide 9: Impact on Healthcare Cost
Impact on Healthcare Cost □ Healthcare costs for persons with type 2 diabetes cost approximately 2.5x as much as a person without diabetes. If they experience complications, that number soars even higher 10 □ Employers and healthcare insurers are therefor resorting to programs that will provide long
Slide 10: Product Portfolio
Product Portfolio sugarBEAT® Non - invasive CGM BEAT ® diabetes Program Consumer Metabolic Health App & Glucose Sensor Kit
Slide 11: sugarBEAT CE approved Class IIB Medical Device
CE approved Class IIB Medical Device US FDA PMA approval and launch in the US anticipated by end of 2021
Slide 12: sugarBEAT CE approved Class IIB Medical Device
CE approved Class IIB Medical Device US FDA PMA approval and launch in the US anticipated by end of 2021 The world’s first daily wearable Continuous Glucose Monitor that doesn’t use needles. CE Approved Class IIb Medical Device
Slide 13: How it works
How it works Apply the sensor Position the daily disposable Sensor and Transmitter on your arm.
Slide 14: How it works
How it works @ See changes as they happen Helps you understand ee your unique glucose 2 foe (94) Gs trend line and lifestyle SS choices taken.
Slide 15: How it works
How it works YesYouCan BEAT™diabetes B contr manage, take d even prevent the onset of Type 2 Diabetes.
Slide 16: Why is sugarBEAT Different?
Why is sugarBEAT ® Different? User does not insert a 1 cm long Filament in the arm using a large needle (like competing invasive sensors) and keep it there for 10 - 15 days . The sensor sits on top of the arm/skin like a band aid . User does not keep the sensor on the skin for 10 - 14 days, the sens
Slide 17: sugarBEAT and Time in Range
sugarBEAT ® and Time in Range A critical advantage of CGM - based systems is the ability to measure the time that glucose levels are in normal range – i . e . , time in range (TIR) . Control over TIR leads to a significant reduction in the onset of complications of diabetes . The same HbA 1 C values
Slide 18: sugarBEAT vs. HbA1C
sugarBEAT ® vs. HbA1C 40% high range 40% in range 20% low range 70% high range 25% in range 5% low range 100% in range The same HbA1C value, yet 3 completely different TIR profiles, demonstrating the power of TIR over HbA1C as the new gold standard 11
Slide 19: sugarBEAT Testimonials
sugarBEAT ® Testimonials * My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, an
Slide 20: sugarBEAT Sales status UK
sugarBEAT ® Sales status UK: UK: 200,000 Sensors ordered by licensee following soft launch success Purchase order forecast for (approximately) a further 100,000 sensors per month for the next 2 years, totaling over 2 million sensors. Licensee selling these based on a diabetes management subscription
Slide 21: sugarBEAT Germany
sugarBEAT ® Germany Partnership/Collaboration discussions ongoing Submission for reimbursement made to GBA, the German Regulatory Authority. GBA confirmed they do not need to review this and it is now progressing straight to the National Association of Statutory Health Insurance Funds, thus we expec
Slide 22: sugarBEAT MENA
sugarBEAT ® MENA Partnered with TPMENA Registration for Saudi A rabia and UAE in progress Plan to launch on completion of registration
Slide 23: BEAT diabetes
BEAT DIABETES
Slide 24: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 25: BEAT diabetes – Components
BEAT ® diabetes – 3 Components 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass 1. pr
Slide 26: BEAT diabetes – Glucose Profiling
BEAT ® diabetes – Glucose Profiling Intermittent Glucose Profiling: Benefits 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on SMBG. Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP, diastolic BP, and LDL Cholesterol Kem
Slide 27: BEAT diabetes Potential Outcome for Payers
BEAT ® diabetes Potential Outcome for Payers Healthier Employees = Healthier Business $1,600 $4,700 $6,600 $9,100 Healthy (No conditions) Prediabetes only Hypertension Only Diabetes Only Annual Cost per Employee On average, diabetes costs both employers and insurers over $9,000 per year. Potential s
Slide 28: BEAT diabetes Current Status
BEAT ® diabetes Current Status First Pilot Commenced, with approx. 200 participants planned for a program of up to 2 years. Anticipate multiple parallel additional pilots in near term
Slide 29: BEAT Metabolic Health
BEAT Metabolic Health Metabolism is life. Can we help 87 MILLION people in the USA from becoming Diabetic using our low cost wearable glucose sensor and digital ecosystem?
Slide 30: Metabolic Health
Metabolic Health A mass - market consumer product A new program leveraging off the BEAT® wearable sensor platform to address improvements in metabolic health and well - being . Launching in 2021. Applicable to over 80 million people in the US with pre - diabetes as well as general health - conscious
Slide 31: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 32: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Globa
Slide 33: Future Product Opportunities Leveraging the BEAT Technology
BIG DATA Predictive analytics based on logic drawn from wearable medical devices using algorithms to seek patterns and structure in data and cluster them into groups or insights. Improving efficiencies per patient’s management of health care. Accuracy of diagnosis and treatment in personal medicine.
Slide 34: The Team
The Team We are building a world class team So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Roche, Abbvie , & Eli Lilly
Slide 35: Intellectual Property
Intellectual Property □ Nemaura is building an extensive and valuable intellectual property portfolio to position the company to become a global leader in the non - invasive wearable sensor market . □ Nemaura has over 30 patents across several patent families (both approved and pending), and substan
Slide 36: Future Milestones
Future Milestones We expect to report the following over the coming months: - Progress with sales of sugarBEAT ® in multiple territories - Commencement of KOL studies in the UK and USA - Launch of the Metabolic Health App & Sensor Kit - Adoption of BEAT ® diabetes program/pilot studies in the USA -
Slide 37: Cash Position
Cash Position As of 26 th July 2021: Strong balance sheet (>$30M, and <$2M quarterly cash burn)
Slide 38: References
References 1. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures. htm! 3. https://www.prnewswire.com/news-releases/global-digital-diabetes-market- outlook-to-2026-a-16-billion-industry-opportunity-300980794.htm! 4, https://www.absolutemarketsinsights.com/reports/Global-Noninsulin- ‘The